- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Digital Technology: A Double-Edged Sword
Technology offers the promise of engaging patients on a level never seen before.
Technology offers the promise of engaging patients on a level never seen before. The benefits of an engaged patient start with increased compliance-a great thing for pharmaceutical companies-and extend to a more active and empowered consumer of healthcare, and ultimately to better and more affordable outcomes.
But technology is a double-edged sword. Its increasing complexity leads to increasing risk and greater scrutiny.
So what does this mean to Senior Directors and Franchise Leaders at pharmaceutical companies? In this Pharm Exec article, Scott Hansen and Geogg Melick explain why it’s vital to get that technology working right first time.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
